Skip to main content

Advertisement

SpringerLink
Log in

Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Relapse of melanoma after surgical treatment remains a significant clinical problem in need of novel therapies. Vitamin E succinate (VES) is a promising antitumor micronutrient. We evaluated the effect of VES on melanoma dormancy and angiogenesis.

Methods

B16F10 melanoma cells were allografted in mice. The effect of VES on melanoma dormancy was measured by monitoring tumor volume. Tumor vascularity was quantitated with CD31 immunostaining. The expression of vascular endothelial growth factor (VEGF), VEGF receptor 1, and VEGF receptor 2 in tumors was assessed by the intensity of immunostaining. VES effect on secreted VEGF protein and VEGF promoter activity was measured with enzyme-linked immunosorbent assay and transient transfection assay, respectively. Significance was determined by analysis of variance.

Results

VES promoted melanoma dormancy (P=.0019) and inhibited melanoma angiogenesis (P<.0001). VES also significantly suppressed the expression of VEGF, VEGF receptor 1, and VEGF receptor 2 in melanoma tumors (P<.0001). Melanoma VEGF secretion (P=.0077) and melanoma VEGF promoter activity (P<.05) were significantly inhibited by VES.

Conclusion

VES promotes melanoma dormancy and inhibits melanoma angiogenesis. The mechanism of the VES antiangiogenesis effect involves the inhibition of VEGF gene transcription. These findings support future studies of VES in the prevention of melanoma metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee R, Muray T, Bolden S, Wingo P. Cancer statistics 2000.CA Cancer J Clin 2000;50:7–33.

    PubMed  CAS  Google Scholar 

  2. Balch CM, Buzaid AC, Soong SJ, et al. Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J Clin Oncol 2001;19:3622–34.

    PubMed  CAS  Google Scholar 

  3. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide.Semin Surg Oncol 1992;8:400–14.

    Article  PubMed  CAS  Google Scholar 

  4. Lotze MT. Cutaneous melanoma. In: Vincent T, DeVita J, eds.Cancer: Principles and Practice of Oncology. 6th ed. Philadelphi: Lippincott Williams & Wilkins, 2001:2012–70.

    Google Scholar 

  5. Kirkwood JM. Ajuvant interferon in the treatment of melanoma.Br J Cancer 2000;82:1755–6.

    Article  PubMed  CAS  Google Scholar 

  6. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.J Clin Oncol 2001;19:2370–80.

    PubMed  CAS  Google Scholar 

  7. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis.Surg Oncol Clin North Am 2001;10:257–69, vii–viii.

    CAS  Google Scholar 

  8. Barnhill RL, Piepkorn MW, Cochran WR, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases.Arch Dermatol 1998;134:991–4.

    Article  PubMed  CAS  Google Scholar 

  9. Barnhill RI. The biology of melanoma micrometastases.Recent Results Cancer Res 2001;158:3–13.

    PubMed  CAS  Google Scholar 

  10. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma.Lab Invest 1992;67:331–7.

    PubMed  CAS  Google Scholar 

  11. Denijn M, Ruiter DJ. The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.Melanoma Res 1993;3:5–14.

    Article  PubMed  CAS  Google Scholar 

  12. Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma.Ann Surg Oncol 1999;6: 70–4.

    Article  PubMed  CAS  Google Scholar 

  13. Ribati D, Vacca A, Palma W, Lospalluti M, Dammacco F. Angiogonesis during tumor progression in human malignant melanoma.EXS 1992;61:415–20.

    Google Scholar 

  14. Folkman J. What is the role of angiogenesis in metastasis from cutaneous melanoma?Eur J Cancer Clin Oncol 1987;23:361–3.

    Article  PubMed  CAS  Google Scholar 

  15. Folkman J. Tumor angiogenesis: therapeutic implications.N Engl J Med 1971;285:1182–6.

    Article  PubMed  CAS  Google Scholar 

  16. Folkman J. What is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst 1990;82:4–6.

    Article  PubMed  CAS  Google Scholar 

  17. Folkman J. The role of angiogenesis in tumor growth.Semin Cancer Biol 1992;3:65–71.

    PubMed  CAS  Google Scholar 

  18. Folkman J. Angiogenesis-dependent diseases.Semin Oncol 2001; 28;536–42.

    Article  PubMed  CAS  Google Scholar 

  19. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell 1996;86:353–64.

    Article  PubMed  CAS  Google Scholar 

  20. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor.Endocr Rev 1997;18:4–25.

    Article  PubMed  CAS  Google Scholar 

  21. Mowlavi A, Malafa MP. Angiogenesis in primary tumor cells of metastatic and nonmetastatic malignant melanoma.Plast Reconstr Surg 2000;106:514.

    Article  PubMed  CAS  Google Scholar 

  22. Vlaykova T, Laurila P, Muhonen T, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.Melanoma Res 1999;9:59–68.

    Article  PubMed  CAS  Google Scholar 

  23. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.J Clin Oncol 2001;19:577–83.

    PubMed  CAS  Google Scholar 

  24. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma.Br J Cancer 1997;76:930–4.

    PubMed  CAS  Google Scholar 

  25. Mardoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase.J Cutan Pathol 1997;24: 212–8.

    Article  Google Scholar 

  26. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis.Melanoma Res 1997;7(Suppl 2):S19–26.

    Google Scholar 

  27. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.Cancer Res 1996;56:172–81.

    PubMed  CAS  Google Scholar 

  28. Oku T, Tjuvajev JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.Cancer Res 1998; 58:4185–92.

    PubMed  CAS  Google Scholar 

  29. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth.J Investig Dermatol Symp Proc 2000;5:24–33.

    Article  PubMed  CAS  Google Scholar 

  30. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.Cancer Res 1987;47:5155–61.

    PubMed  CAS  Google Scholar 

  31. Prasad KN, Edwards-Prasad J. Vitamin E and cancer prevention: recent advances and future potentials.J Am Coll Nutr 1992;11: 487–500.

    PubMed  CAS  Google Scholar 

  32. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy.J Surg Res 2000;93:163–70.

    Article  PubMed  CAS  Google Scholar 

  33. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice.Surgery 2002;131:85–91.

    Article  PubMed  Google Scholar 

  34. Shklar G, Schwartz JL. Vitamin E inhibits experimental carcinogenesis and tumour angiogenesis.Eur J Cancer B Oral Oncol 1996;32B:114–9.

    Article  PubMed  CAS  Google Scholar 

  35. Barnett KT, Fokum FD, Malafa MP. Vitamin E succinate inhibits colon cancer liver metastases.J Surg Res 2002;106:292.

    Article  PubMed  CAS  Google Scholar 

  36. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.Science 1992;255:989–91.

    Article  PubMed  Google Scholar 

  37. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine gene (flt) closely related to the fms family.Oncogene 1990;5:519–24.

    PubMed  CAS  Google Scholar 

  38. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.Biochem Biophys Res Commun 1992; 187:1579–86.

    Article  PubMed  CAS  Google Scholar 

  39. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.EMBO J 1996;15:290–8.

    PubMed  CAS  Google Scholar 

  40. Waltenberger JH, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C. Differential signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.Biol Chem 1994;269:26988–95.

    CAS  Google Scholar 

  41. Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.Growth Factors 1996;13:57–64.

    PubMed  CAS  Google Scholar 

  42. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis.Semin Cancer Biol 1999;9:211–20.

    Article  PubMed  CAS  Google Scholar 

  43. Shi Q, Le X, Abbruzzese JL, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.Cancer Res 2001;61:4143–54.

    PubMed  CAS  Google Scholar 

  44. Barnhill RL, Piepkorn MW, Cochran AJ, Flyn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases.Arch Dermatol 1998;134:991–4.

    Article  PubMed  CAS  Google Scholar 

  45. Sokol RJ, Butler-Simon N, Conner C, et al. Multicenter trial of d-alpha-tocoepheryl polythylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis.Gastroenterology 1993;104:1727–35.

    PubMed  CAS  Google Scholar 

  46. Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis.Methods Enzymol 2001;333:267–83.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois

    Mokenge P. Malafa MD, Frida D. Fokum PhD, LaKesha Smith & Audreen Louis

Authors
  1. Mokenge P. Malafa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frida D. Fokum PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. LaKesha Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Audreen Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mokenge P. Malafa MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malafa, M.P., Fokum, F.D., Smith, L. et al. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Annals of Surgical Oncology 9, 1023–1032 (2002). https://doi.org/10.1007/BF02574523

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02574523

Key Words

Search

Navigation